These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 26996175)
1. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome. Iulita MF; Caraci F; Cuello AC CNS Neurol Disord Drug Targets; 2016; 15(4):434-47. PubMed ID: 26996175 [TBL] [Abstract][Full Text] [Related]
2. The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. Iulita MF; Cuello AC Curr Alzheimer Res; 2016; 13(1):53-67. PubMed ID: 26391047 [TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. Iulita MF; Cuello AC Trends Pharmacol Sci; 2014 Jul; 35(7):338-48. PubMed ID: 24962069 [TBL] [Abstract][Full Text] [Related]
4. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. Do Carmo S; Kannel B; Cuello AC Cells; 2021 Dec; 11(1):. PubMed ID: 35011577 [TBL] [Abstract][Full Text] [Related]
5. Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology. Cuello AC Adv Exp Med Biol; 2021; 1331():119-144. PubMed ID: 34453296 [TBL] [Abstract][Full Text] [Related]
6. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model. Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402 [TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor metabolic dysfunction in Down's syndrome brains. Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975 [TBL] [Abstract][Full Text] [Related]
8. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. Baker-Nigh A; Vahedi S; Davis EG; Weintraub S; Bigio EH; Klein WL; Geula C Brain; 2015 Jun; 138(Pt 6):1722-37. PubMed ID: 25732182 [TBL] [Abstract][Full Text] [Related]
9. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Iulita MF; Bistué Millón MB; Pentz R; Aguilar LF; Do Carmo S; Allard S; Michalski B; Wilson EN; Ducatenzeiler A; Bruno MA; Fahnestock M; Cuello AC Neurobiol Dis; 2017 Dec; 108():307-323. PubMed ID: 28865749 [TBL] [Abstract][Full Text] [Related]
10. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181 [TBL] [Abstract][Full Text] [Related]
11. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Cuello AC; Bruno MA; Bell KF Curr Alzheimer Res; 2007 Sep; 4(4):351-8. PubMed ID: 17908036 [TBL] [Abstract][Full Text] [Related]
12. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Cuello AC; Bruno MA Neurochem Res; 2007 Jun; 32(6):1041-5. PubMed ID: 17404842 [TBL] [Abstract][Full Text] [Related]
13. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555 [TBL] [Abstract][Full Text] [Related]
14. The cholinergic system in aging and neuronal degeneration. Schliebs R; Arendt T Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918 [TBL] [Abstract][Full Text] [Related]
15. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Fahnestock M; Michalski B; Xu B; Coughlin MD Mol Cell Neurosci; 2001 Aug; 18(2):210-20. PubMed ID: 11520181 [TBL] [Abstract][Full Text] [Related]
16. A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. Pentz R; Iulita MF; Mikutra-Cencora M; Ducatenzeiler A; Bennett DA; Cuello AC Neurobiol Dis; 2021 Jan; 148():105150. PubMed ID: 33130223 [TBL] [Abstract][Full Text] [Related]
17. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. Cuello AC; Bruno MA; Allard S; Leon W; Iulita MF J Mol Neurosci; 2010 Jan; 40(1-2):230-5. PubMed ID: 19680822 [TBL] [Abstract][Full Text] [Related]
18. Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. Xu W; Weissmiller AM; White JA; Fang F; Wang X; Wu Y; Pearn ML; Zhao X; Sawa M; Chen S; Gunawardena S; Ding J; Mobley WC; Wu C J Clin Invest; 2016 May; 126(5):1815-33. PubMed ID: 27064279 [TBL] [Abstract][Full Text] [Related]
19. Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer's Disease Identifies a Need for Improved Vector Delivery. Castle MJ; Baltanás FC; Kovacs I; Nagahara AH; Barba D; Tuszynski MH Hum Gene Ther; 2020 Apr; 31(7-8):415-422. PubMed ID: 32126838 [TBL] [Abstract][Full Text] [Related]
20. ProNGF, sortilin, and age-related neurodegeneration. Al-Shawi R; Hafner A; Chun S; Raza S; Crutcher K; Thrasivoulou C; Simons P; Cowen T Ann N Y Acad Sci; 2007 Nov; 1119():208-15. PubMed ID: 18056969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]